E193: GLP-1s, AI & the End of Sick Care: The Next $10B Health Tech Giant
What if your healthcare wasn't about just treating sickness, but maximizing your potential? In today's episode on How I Invest, I spoke with Dr. Cameron Sepah, founder and CEO of Maximus, a performance medicine company pioneering a new paradigm in healthcare. Cameron previously helped build Omada Health, now a…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from How I Invest with David Weisburd
See all episodes →
36%E451: Peter Thiel's 27-Year Partner on the AI Bubble, the Venture Capital Crisis, and the PayPal Mafia
36%E449: Federated Hermes CEO on $400 Billion in Cash, the Private Markets Boom, and AI
33%E454: True Anomaly’s Even Rogers on Space Warfare, China’s Military Advantage, and the Defense Tech Boom
Similar episodes from other shows
More like How I Invest with David Weisburd →
GLP-1s Explained: Weight Loss, Side Effects, and What They Can Really Do
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
#1 Monthly. Peptides, FDA Approval & Longevity Trends: Dr. Myles Spar Separates Science From Hype
GLP-1s: The Miracle Drug Changing Weight Loss & Medicine Forever (ft. Bracha Banayan) | SNH #116
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.